Secreted Frizzle-Related Protein 2 Stimulates Angiogenesis via a Calcineurin/NFAT Signaling Pathway

Andrew Courtwright, Sharareh Siamakpour-Reihani, Jack L. Arbiser, Natalie Banet, Eleanor Hilliard, Levi Fried, Chad Livasy, David Ketelsen, Desh Bandhu Nepal, Charles M. Perou, Cam Patterson, and Nancy Klauber-DeMore

Abstract

Secreted frizzle-related protein 2 (SFRP2), a modulator of Wnt signaling, has recently been found to be overexpressed in the vasculature of 85% of human breast tumors; however, its role in angiogenesis is unknown. We found that SFRP2 induced angiogenesis in the mouse Matrigel plug assay and the chick chorioallantoic membrane assay. SFRP2 inhibited hypoxia induced endothelial cell apoptosis, increased endothelial cell migration, and induced endothelial tube formation. The canonical Wnt pathway was not affected by SFRP2 in endothelial cells; however, a component of the noncanonical Wnt/Ca2+ pathway was affected by SFRP2 as shown by an increase in NFATc3 in the nuclear fraction of SFRP2-treated endothelial cells. Tacrolimus, a calcineurin inhibitor that inhibits dephosphorylation of NFAT, inhibited SFRP2-induced endothelial tube formation. Tacrolimus 3 mg/kg/d inhibited the growth of SV40 angiosarcoma xenografts in mice by 46% (P = 0.04). In conclusion, SFRP2 is a novel stimulator of angiogenesis that stimulates angiogenesis via a calcineurin/NFAT pathway and may be a favorable target for the inhibition of angiogenesis in solid tumors.

Introduction

Angiogenesis is the growth of new capillary blood vessels and is a critical component of solid tumor growth (1). Limiting angiogenesis through blockade of vascular endothelial growth factor has resulted in an increase in overall or progression-free survival in patients with metastatic breast (2), colon (3), lung (4), and renal cell carcinoma (5). There is a need for new angiogenesis inhibitors because not all tumors respond equally well to anti-vascular endothelial growth factor therapy, and most tumors eventually progress. Recognizing that tumor neovessels differ from normal vasculature, we developed a novel method for immunolaser capture microdissection coupled with RNA amplification and genome-wide gene expression to profile tumor vasculature cells from human breast tumors compared with normal breast samples (6). In our analysis, the largest sample number to date of breast tumor vasculature, we identified 55 genes with >4-fold increased expression compared with normal. Secreted frizzle-related protein 2 (SFRP2) mRNA was increased >6-fold in breast cancer endothelium, and as shown by immunohistochemistry, 33 of 39 (85%) of breast tumors showed intense staining for SFRP2 in the neovasculature. Importantly, SFRP2 was highly expressed in the vasculature of luminal, HER-2/neu, and basal tumors (6).

In our present study, we evaluated the vascular expression of SFRP2 in angiosarcoma, colon cancer, prostate cancer, lung cancer, ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, and pancreatic cancer and found that SFRP2 is strongly expressed in all tumors, making SFRP2 a broad-spectrum vascular target. Based on the expression of SFRP2 in vascular endothelium, we hypothesize that SFRP2 stimulates angiogenesis. We sought to associate a function with SFRP2 expression in endothelial cells using in vivo and in vitro angiogenesis models.

Materials and Methods

Chick chorioallantoic membrane assay. Fertilized chickens eggs (NC State University Chicken Research Farm) were incubated at 100°F in an egg turner for 4 days and then cracked into sterile Petri dishes and incubated at 99°F, 3% CO2, and 65% humidity. For application of drug onto the chick chorioallantoic membrane (CAM), Whatman grade 1 filter paper was cut into circles with a 6 mm diameter paper punch and autoclaved, soaked in 1 mL of 3.0 mg/mL cortisone acetate in absolute ETOH, and air-dried for 60 min in laminar flow hood. On day 8, five disks per egg were placed on outer third of CAM, 2 to 3 mm from a vessel. Control 0.1% bovine serum albumin in PBS 7 μL was added to the discs for the control CAMs, and recombinant murine SFRP2 (US Biologicals) 100 ng/7 μL of 0.1% bovine serum albumin in PBS was added to the disks for the treated CAMs (n = 13 control disks and 23 SFRP2-treated disks). The CAMs were evaluated under stereomicroscope on day 3 after disk placement. Pictures of the area around the disk were taken with a Wild M-470 Macrosystem, and angiogenesis was quantified using Metamorph Software with an angiogenesis module.

Mouse Matrigel plug angiogenesis assay. Mouse studies were approved by Institutional Animal Care and Use Committee at University of North Carolina. The Matrigel plug assay was done as described previously (7). Female C57BL/6 mice (8 weeks old) were injected subcutaneously with 0.5 mL growth factor-reduced basement membrane matrix (Matrigel) from BD Biosciences containing either mouse recombinant SFRP2 (800 ng/mL) with 30 units/mL heparin (American Pharmaceutical Partners) or PBS with 30 units/mL heparin for negative control was injected subcutaneously on the back. Two to three Matrigel plugs were injected per mouse. Seven days later, the mice were sacrificed and the Matrigel plugs were removed and evaluated for angiogenesis by hemoglobin concentration with the Drabkin’s reagent (3). Antibodies. The following antibodies were purchased from Santa Cruz Biotechnology: β-catenin antibody (sc-59893; 1:500 dilution), NFATc1 (sc-7294; 1:500 dilution), NFATc2 (sc-7296; 1:500 dilution), NFATc3 (sc-8405; 1:250 dilution for Western blot and 1:100 dilution for immunohistochemistry), H-Ras (sc-29; 1:500 dilution), and FRP2 (sc-13940; 1:500 dilution).
dilution for Western blot and 1:100 dilution for immunohistochemistry). The β-tubulin loading control (ab6046) was purchased from Abcam and used in 1:1,000 dilution. The following secondary antibodies were purchased from GE Healthcare Bio-Sciences: ECL anti-mouse IgG, horseradish peroxidase-linked whole antibody (NA931), and ECL anti-rabbit IgG, horseradish peroxidase-linked whole antibody (NA934) with 1:100,000 dilution.

Cell culture. Human coronary artery endothelial cells (HCAEC) were purchased from Clonetics. HCAEC were cultured in endothelial cell basal medium-2 with BulletKit growth supplements (Clonetics). Mouse myocardial endothelial cells (MEC) from Robert Auerbach (University of Wisconsin) were grown in low-glucose DMEM (Life Technologies) with 10% fetal bovine serum (HyClone). SVR angiosarcoma cells were obtained from Dr. Jack Arbiser (Emory University Medical School) and cultured in low-glucose DMEM with 10% fetal bovine serum.

Endothelial cell apoptosis. HCAEC were used for apoptosis assays because we were not able to induce apoptosis with hypoxia in the MEC. HCAEC were grown in 10 cm dishes (Becton Dickinson) with until 80% confluent. Medium was replaced with endothelial cell basal medium-2 without BulletKit growth supplements and 70 or 700 pmol/L SFRP2 was added to the cells. The plate was incubated in hypoxic conditions (37°C in a hypoxia chamber with an atmosphere of 5% CO2/94% N2 with an oxygen level of 1.0%) for 36 h. Apoptosis was measured by the activity of cleaved caspase-3 by using a caspase-specific fluorogenic substrate according to the manufacturer’s instructions. MEC were seeded onto the matrix at a concentration of 1 × 10⁴ per well in 150 μL DMEM with 10% fetal bovine serum. A 7 pmol/L to 7 nmol/L dose curve of mouse recombinant SFRP2 was added to the wells and the plates were returned to 37°C, 5% CO₂ for 8 h. Images were acquired using the Nikon Eclipse TS100 microscope at ×4 magnification with a Nikon CoolPix 995 digital camera. Results were quantified by counting the number of branch points.

For tacrolimus treatment experiments, MEC were treated as above with SFRP2 30 nmol/L with and without tacrolimus (LC Laboratories) at concentrations ranging from 1 to 100 μmol/L for 8 h and branch points were determined as described above. Inhibition of SVR angiosarcoma tube formation by a polyclonal antibody to SFRP2 (Santa Cruz Biotechnology) was done after removing sodium azide from the SFRP2 antibody using Zeba Desalt Spin Columns (Pierce Biotechnology). SVR cells were plated onto extracellular matrix as above and a dilution curve of SFRP2 antibody (1:10-1:10,000) was added to the wells. Results were quantified by counting the number of branch points.

Small interfering RNA to SFRP2 in SVR angiosarcoma cells. SVR cells were transfected with 72 μmol/L small interfering RNA (siRNA) for SFRP2 [siRNA 1: siFPR2 (sc-40001); Santa Cruz Biotechnology], which is a pool of three target-specific 20- to 25-nucleotide siRNAs designed to knock down SFRP2 gene expression. The three sequences are 5′-GAGAUAACGUACAUCAACA-3′, 5′-CAAGCUCAUGCUAGUUU-3′, and 5′-CAUGUCAGGAAUUGUU-3′. The sham siRNA (sc-36869; Santa Cruz Biotechnology) contains a scrambled sequence that does not lead to the specific degradation of any known cellular mRNA. SVR cells were maintained in DMEM with 10% FCS. After 72 h of transfection using Lipofectamine RNAiMAX Transfection reagent (Invitrogen) according to the manufacturer’s protocol, cells were

Figure 1. SFRP2 protein is present in the endothelium of a wide variety of tumor types by immunohistochemistry. Paraffin-embedded sections of human tumors were stained with an antibody to SFRP2 as described in Materials and Methods. Magnification, ×600. Ca, cancer.
harvested for Western blot analyses and tube formation assay. Cells were seeded for a 4 h tube formation assay as described above.

**Western blot analyses.** MEC were grown to 90% confluence followed by the change of medium with and without mouse recombinant SFRP2 (700 pmol/L). Cells were incubated for 1, 2, 4, 8, and 16 h with SFRP2. MS1 and SVR cells were grown to 80% to 90% confluence. Nuclear and cytoplasmic proteins were extracted by using NE-PER nuclear and cytoplasmic extraction reagent (Pierce Biotechnology). The whole-cell lysates were obtained using M-PER Mammalian Protein Extract reagent (Pierce Biotechnology) as described in the manufacturer’s manual. Protein concentration was measured using Bio-Rad Protein Assay at A595 (Bio-Rad Laboratories). Equal amount of protein (20 μg) was loaded onto SDS-PAGE gels. Proteins were transferred to polyvinylidene difluoride membrane, and Western blotting was carried out using the proper primary antibody, with horseradish peroxidase-conjugated IgG as the secondary antibody. The ECL Advance substrate was used for visualization (GE Healthcare Bio-Sciences).

**Immunohistochemistry.** Immunohistochemistry with antibodies to SFRP2 was done on paraffin-embedded human angiosarcoma, colon cancer, prostate cancer, lung cancer, ovarian cancer, pancreatic cancer, hepatocellular carcinoma, and renal cell carcinoma as described previously (6). Immunohistochemistry with antibodies to NFATc3 was done on paraffin-embedded human angiosarcoma. Tissues were sectioned at 8 μm, and 250 μL primary antibody (SFRP2 1:100 or NFATc3 1:100) was applied. A negative control without primary antibody was done. Two pathologists (C.L. and N.O.) scored each tissue section for SFRP2 and NFATc3 expression based on intensity of stain in endothelium and percent positive endothelial cells staining.

**Tumor growth in vivo.** Mouse studies were approved by Institutional Animal Care and Use Committee at Emory University. SVR cells (0.5 × 106) were injected into the flank of 6-week-old nude male mice obtained from Charles River Breeding Laboratories. Treatment was initiated on the day after inoculation. Mice received 3 mg/kg/d tacrolimus or vehicle control suspended in 20% Intralipid (Baxter Healthcare) in a total volume of 0.3 mL intraperitoneally and were treated daily for 19 days. Serial caliper measurements of perpendicular diameters were used to calculate tumor volume using the following formula: (shortest diameter)² × (longest diameter) × 0.52.

**Statistics.** Statistical differences for in vitro assays, Western blot analyses, CAM assay, and mouse Matrigel plug assay were done with a two-tailed Student’s t test, as the data from these experiments were normally distributed, with P < 0.05 being significant. For the in vivo mouse tumor growth experiment, differences in tumor volume over time were analyzed with a two-way ANOVA. P ≤ 0.05 indicated a statistically significant reduction in tumor growth of the treated group compared with the control group.

**Results**

**SFRP2 vascular expression in tumors.** We performed immunohistochemistry with antibodies to SFRP2 in seven different tumor types and evaluated the intensity of staining in the vessels and the percent of endothelial staining. All tumor studies (prostate cancer n = 7, angiosarcoma n = 9, hepatocellular carcinoma n = 7, colon cancer n = 8, clear-cell renal carcinoma n = 8, lung cancer n = 8, ovarian cancer n = 8, and pancreatic cancer n = 6) had 3+ vessel intensity staining in the tumor vasculature with the majority of endothelium staining positive in most tumors (Fig. 1; Supplementary Fig. S1), showing that SFRP2 is a vascular target in a broad variety of tumors.

**SFRP2 stimulates angiogenesis in vivo.** We implanted SFRP2 (n = 23) impregnated filter paper or control (n = 13) on the developing CAM on day 8. After 3 days, SFRP2 induced angiogenesis on the CAM with a statistically significant increase in number of branch points, segments, tube percent area covered (0.004), total tube area (0.008), and total tube length (0.008; Fig. 2A). This observation on the CAM indicates that SFRP2 is a stimulator of angiogenesis.

The angiogenic capacity of SFRP2 was confirmed by the mouse Matrigel plug assay. Seven days after injection into mice, the
control Matrigel plugs containing PBS and 30 units/mL heparin and SFRP2 (800 ng) + 30 units/mL heparin Matrigel containing plugs were removed. Evaluation of the angiogenic response by measurement of hemoglobin content showed a 3.3-fold increase in SFRP2 plugs compared with the vehicle control (*n* = 25 SFRP2 plugs and *n* = 26 control plugs; *P* = 0.01; Fig. 2B-D).

**SFRP2 promotes cellular processes required for angiogenesis.** To explore the cellular mechanism through which SFRP2 promotes angiogenesis, we evaluated the effects of SFRP2 on endothelial cell migration, proliferation, apoptosis, and tube formation, which are all important steps in the angiogenesis cascade (9). The effect of SFRP2 on the migration properties of endothelial cells was evaluated using a scratch wound assay. At 16 h, control mouse endothelial cells (MEC) migrated 480 ± 23 μm and SFRP2 (700 pmol/L)-treated MEC migrated 680 ± 40 μm (*P* < 0.02; Fig. 3A).

SFRP2 (7 pmol/L-7 nmol/L) had no effect on MEC or HCAEC proliferation at 24, 48, or 72 h (data not shown). However, SFRP2 protected against hypoxia-induced HCAEC apoptosis. Treatment with hypoxia alone in HCAEC resulted in a 6-fold increase in apoptosis compared with cells in normoxia. Hypoxia does not induce apoptosis in MEC; therefore, the effect of SFRP2 on MEC
apoptosis was not evaluable. Addition of SFRP2 (70 and 700 pmol/L) to hypoxic HCAEC decreased apoptosis by 55 ± 9% (n = 4 per group; P < 0.02; Fig. 3B).

MEC tube formation was induced by SFRP2 in a concentration-dependent manner at 8 h (P = 0.0006 at 7 nmol/L; n = 4 per group; Fig. 3C). Taken together, these in vitro experiments show that SFRP2 induces migration, antiapoptosis, and tube formation, which are important cellular processes necessary for new blood vessel formation.

To study whether loss of function of SFRP2 would inhibit tube formation, we used a model of a highly vascularized malignant endothelial tumor, the SVR angiosarcoma tumor model, which was derived from the transfection of Ras into MS1 endothelial cells. MS1 cells were previously generated by immortalizing murine endothelial cells by expressing the temperature-sensitive large T antigen (10). On implantation into mice, these cells form dormant hemangiomas (10). MS1 cells were then transfected with Ras (SVR), and this cell line forms angiosarcomas when injected into nude mice (10).

We collected protein lysates from MS1 and SVR cells and, using Western blot analyses probing for SFRP2, found that SFRP2 was increased in SVR cells compared with MS1 cells (Fig. 4A), which correlated with H-RAS overexpression. We then transfected SVR angiosarcoma cells with siRNA to SFRP2 or sham control and evaluated tube formation in a Matrigel assay. siRNA-transfected SVR cells had 70% fewer branch points compared with sham-transfected cells (sham control = 267 ± 33 branch points and siRNA SFRP2-transfected cells = 65 ± 10 branch points; P = 0.001; n = 4 per group; Fig. 4B). We then treated SVR cells in a tube formation assay with a polyclonal antibody to SFRP2 and found inhibition of SVR tube formation in a concentration-dependent manner (Fig. 4C).

Effects of SFRP2 on molecular signaling pathways in endothelial cells. To begin to elucidate the molecular mechanism of SFRP2 in angiogenesis, we first investigated whether SFRP2 inhibited the canonical Wnt pathway, because SFRP2 has been reported to inhibit this signaling pathway in other cell types (11).
We compared protein levels of dephosphorylated nuclear β-catenin in control and SFRP2-treated MEC. SFRP2 (30 nmol/L) decreased nuclear β-catenin in SFRP2-stimulated endothelial cells at 1 h (Supplementary Fig. S2). However, at 700 pmol/L, which is the dose of SFRP2 that induced migration and tube formation in MEC, there was no statistically significant change in nuclear β-catenin in the SFRP2-stimulated endothelial cells at 1 h ($n=6$ per group; Fig. 3A) or at 2, 4, 8, and 16 h (data not shown). This suggests that although SFRP2 may inhibit the canonical Wnt pathway in endothelial cells, it is likely that the angiogenic effects of SFRP2 are being mediated through a noncanonical pathway, because the canonical pathway was not inhibited at the lower concentrations of SFRP2, which induce angiogenesis.

We next evaluated the role of the noncanonical Wnt/Ca$^{2+}$ pathway in SFRP2-induced angiogenesis. When the noncanonical Wnt/Ca$^{2+}$ pathway is activated, calcineurin dephosphorylates NFAT in the cytoplasm, allowing NFAT to translocate into the nucleus and act as a transcription factor (12). We found that NFATc3 was increased at 1 h in the nuclear fraction of SFRP2-treated MEC (Fig. 5B). There was no change in NFATc1 or NFATc2 in SFRP2-treated endothelial cells (data not shown). This suggests that SFRP2 is signaling through the Wnt/Ca$^{2+}$ pathway and induces NFAT nuclear translocation in endothelial cells.

**NFATc3 expression in human angiosarcoma.** To correlate our *in vitro* finding of increased NFATc3 expression in SFRP2-treated endothelial cells with *in vivo* data, we performed immunohistochemistry with antibodies to NFATc3 on paraffin-embedded human angiosarcomas and found that 6 of 8 tumors stained positive for NFATc3 (Supplementary Fig. S3).

**Tacrolimus inhibits SFRP2-induced tube formation and tumor growth *in vivo.** If SFRP2 stimulates angiogenesis via the calcineurin/NFAT pathway, then pharmacologic inhibition of NFAT should inhibit SFRP2-induced angiogenesis. To test this hypothesis, we studied whether tacrolimus would inhibit SFRP2-mediated angiogenesis. Tacrolimus (FK506) binds to the immunophilin FKBP12. The FK506-FKBP12 complex associates with calcineurin and inhibits its phosphatase activity, which inhibits nuclear translocation of NFAT (13). Therefore, we treated MEC in a tube formation assay with SFRP2 with and without tacrolimus. Tacrolimus (1 μmol/L) inhibited SFRP2-induced MEC tube formation by 64% ($P=0.002; n=3$ per group; Fig. 3D). Tacrolimus was not cytotoxic to MEC, as only 5% of tacrolimus-treated cells took up trypan blue dye (data not shown). This provides further support for the role of NFAT in SFRP2-stimulated tube formation.

We then treated mice with SVR angiosarcoma xenografts with tacrolimus. Treatment with tacrolimus ($n=12$) at 3 mg/kg/d intraperitoneally for 19 days was effective at suppressing the growth of SVR angiosarcoma tumor in nude mice compared with control ($n=12$). Treatment with tacrolimus reduced mean tumor volume by 46% at day 19 (589 ± 129 versus 315 ± 93 mm$^3$; $P=0.04$, two-way ANOVA; Fig. 6A and B). There were no signs of toxicity (no diarrhea, infection, lethargy, or weight loss) after 19 days of treatment.

**Discussion**

SFRP2 belongs to a large family of SFRPs, which are related to the Wnt signaling cascade, and has been previously implicated in cancer. Some studies suggest that SFRP2 is an inhibitor of the Wnt-β-catenin pathway (11), and these data taken together with reports of epigenetic inactivation of SFRP2 in breast cancer cell lines (14), oral squamous cell carcinoma (15), and hepatocellular carcinoma (16) suggest that SFRP2 may be a tumor suppressor gene. In contrast, several studies provide evidence that suggest that SFRP2 may “induce” tumor growth. For example, SFRP2 has been found to be highly induced in canine mammary gland tumors but not in normal mammary glands (17), and overexpression of transfected SFRP2 in breast adenocarcinoma cells increased their resistance to apoptotic signals (18). Additionally, SFRP2 has also been found to be produced by the majority of malignant glioma cell lines, and SFRP2-overexpressing intracranial glioma xenografts were significantly larger than xenografts consisting of control cells in nude mice (19). Although these studies suggest contrasting views of the role for SFRP2 on tumor epithelium, no study to date has evaluated the contribution of SFRP2 to angiogenesis.
We recently reported that SFRP2 is a novel tumor endothelial marker for breast cancer and is overexpressed in the endothelium of ~85% of human breast tumors, including luminal A, basal, and HER-2/neu subtypes (6). In this article, we now show that SFRP2 is expressed in the vasculature of a wide variety of tumors, including angiosarcoma, renal cell carcinoma, prostate cancer, lung cancer, ovarian cancer, pancreatic cancer, and colon cancer, making SFRP2 a broad-spectrum vascular target. Based on its overexpression in tumor endothelium, we hypothesized that SFRP2 stimulates angiogenesis. We report that SFRP2 is a novel stimulator of angiogenesis in vivo in the mouse Matrigel plug and CAM assays. SFRP2 modulates the cellular processes involved in angiogenesis, including endothelial cell migration, tube formation, and protection against hypoxia-induced endothelial cell apoptosis, and is required for angiosarcoma tube formation.

SFRP2 contains a cysteine-rich domain that is homologous to the putative Wnt binding domain. The Wnt signaling network required for angiosarcoma tube formation.

Figure 6. Tacrolimus inhibits the growth of SVR angiosarcoma xenograft in nude mice. Nude mice were injected with 0.5 × 10^6 SVR tumor cells as described in Materials and Methods. A, tacrolimus 3 mg/kg (n = 12) or control buffer (n = 12) was injected intraperitoneally daily starting the day after tumor implantation. Treatment with tacrolimus reduced mean tumor volume by 46% at day 19 (589 ± 129 versus 315 ± 93 mm^3). *, P = 0.04, two-way ANOVA. B, representative control mouse tumor and representative tacrolimus-treated mouse tumor on day 19 of treatment.

In vivo expression of SFRP2 in SVR tumor. (A) MCF7 cells with stable transfectants of SFRP2 (21), (b) mammary canine tumors with increased expression of SFRP2 (17), and (d) hypoxic adipose tissue-derived stem cells (22). Our study in endothelial cells show that, at the dose of SFRP2 that induces angiogenesis, there is no change nuclear β-catenin, suggesting that β-catenin is not responsible for the angiogenic actions of SFRP2. This led us to investigate whether the angiogenic effects of SFRP2 are mediated through a noncanonical Wnt pathway.

Noncanonical Wnts activate other signaling pathways, such as the Wnt/Ca^2+ pathway (23). The Wnt/Ca^2+ pathway is a β-catenin-independent pathway for which signaling is mediated through Wnt5a binding to the frizzled 5 transmembrane receptor, which leads to a transient increase in cytoplasmic free calcium. This subsequently activates the phosphatase calcineurin. Activated calcineurin dephosphorylates NFAT, which then translocates to the cytoplasm to the nucleus. The NFAT family consists of four members (NFATc1-c4), which exist as transcriptionally inactive, cytosolic phosphoproteins (12). NFAT nuclear localization is dependent on a dynamic import-export balance between the activity of the Ca^2+/calmodulin-dependent phosphatase, calcineurin, and the activity of serine/threonine kinases (12). NFAT cannot normally enter the nucleus until it is dephosphorylated but can be activated by calcineurin. Loss-of-function mutants have shown that NFAT signaling is crucial for normal heart valve and vascular development during embryogenesis (12, 24). Postnatally, this pathway contributes to the regulation of cell growth, differentiation, and cell cycle progression in various cell types, and there are increasing data supporting a critical role of NFAT in mediating angiogenic responses (25, 26). Importantly, NFAT activation was identified as a critical component of vascular endothelial growth factor-induced angiogenesis and linked to the induction of cyclooxygenase-2, which is also a critical player in angiogenesis. NFAT is a crossing point for the endothelial cell survival pathways initiated by proangiogenic vascular endothelial growth factor and basic fibroblast growth factor (26). Based on these observations, we hypothesized that SFRP2 activates NFAT in endothelial cells.

We found that NFATc3 protein was increased in the nucleus after treatment of endothelial cells in vitro with SFRP2 and was present in human angiosarcomas that also expressed SFRP2. Angiosarcoma is a biologically aggressive vascular malignancy with a high metastatic potential and subsequent mortality. The 2- and 5-year overall survival for all patients with angiosarcoma is 50% and 30%, respectively, with a median overall survival of 24 months (27). There is a desperate need for novel therapies to improve survival in patients with this highly lethal disease, and our findings suggest that targeting NFAT may be therapeutic strategy for angiosarcoma.

Tacrolimus is an immunosuppressive drug that binds to the immunophilin FKBP12. The FK506-FKBPI2 complex associates...
with calcineurin and inhibits its phosphatase activity, which inhibits nuclear translocation of NFAT (13). We found that tacrolimus inhibited SFRP2-induced tube formation in vitro and the growth of angiosarcoma xenografts in vivo, suggesting that SFRP2 induces tube formation via a calcineurin-dependent NFAT pathway. Tacrolimus has previously been shown to inhibit growth of a leukemia cell line in mice (28), and our report is the first to our knowledge to show that tacrolimus inhibits angiogenesis in vitro and solid tumor growth in vivo. The mechanism of tacrolimus needs to be distinguished from other drugs used to prevent transplant rejection that are being studied in clinical trials for cancer, such as sirolimus (rapamycin) and everolimus (RAD001, a derivative of rapamycin). These drugs have the same intracellular target as tacrolimus, FKBP12, but unlike tacrolimus these drugs inhibit mammalian target of rapamycin and have no effect on NFAT (29).

In summary, SFRP2, a secreted protein overexpressed in the vasculature of a large variety of human tumors, is a novel angiogenesis stimulator. Our data suggest that SFRP2 mediates angiogenesis via a calcineurin-dependent NFAT pathway and that an inhibitor of the calcineurin-NFAT pathway inhibit tumor growth. Based on its expression pattern and function, SFRP2 and NFAT may be favorable targets for the inhibition of angiogenesis in solid tumors and direct tumor targets in angiosarcoma.

Disclosure of Potential Conflicts of Interest

N. Klauber-DeMore and C. Patterson: “Discovery of Novel Targets for Angiogenesis Inhibition.” Report of Invention Ref. # OTD07-008, patent pending 3/08. The other authors disclosed no potential conflicts of interest.

Acknowledgments

Received 9/2/08; revised 3/18/09; accepted 4/1/09; published OnlineFirst 5/19/09.

Grant support: Department of Defense Physician Scientist Training Award for Breast Cancer Research W81XWH-03-1-0157; University Cancer Research Fund (N. Klauber-DeMore); NIH, National Cancer Institute Breast Cancer Specialized Program of Research Excellence grant P50-CA58223 (N. Klauber-DeMore and C.M. Perou); and Veterans Administration Merit Award, NIH grant RO1 AB02030, Jamie Rabinowitz-Davis Foundation, and Mimik Foundation (J.L. Arbiser).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References